Global spinal fusion bone graft substitutes market is expected to grow substantially owing to increasing demand for minimally invasive surgeries coupled with growing geriatric population, which is correlated with the rising rates of conditions such as Degenerative Disc Disease (DDD), Kyphosis, and Scoliosis. Introduction of technologically advanced substitutes such as nanOss loaded advanced bone graft substitute by RTI Surgical, Grafton by Osteotech, and VITOSS by Orthovita is expected to surge the market growth over the next seven years. The market is rapidly transforming the scenario in the global healthcare industry. In addition, increasing surgeon awareness regarding the benefits of the alternatives to autograft and allograft is also one of the major drivers of the market. Other drivers for this market are changing mindsets of people, growing medical awareness, and benefits associated with minimally invasive surgeries such as high safety and efficacy.
The demand for minimally invasive surgeries is on the rise. These procedures result in fewer traumas to the patient and quicker recovery. Research results published by Ethicon Endo-Surgery Inc. suggest that minimally invasive surgeries are rapidly replacing invasive surgeries owing to higher patient satisfaction, relatively lesser number of hospital stays, lesser number of post-surgery complications, and lower mortality rates. Spinal fusion bone graft substitutes are used in minimally invasive procedures and therefore, the rising demand for minimally invasive surgeries is expected to boost market growth over the forecast period
Introduction of technological advancements on the grounds of osteoinductivity, osteoconductivity, osteogenicity, and cost-effectiveness is expected to serve this market as a growth driver. For example, the introduction of BMP-2 (Infuse) by Medtronics and BMP-7 (OP-1) by Stryker Biotech, which is produced by recombinant technology, provides significantly faster fracture healing.
Based on types of processes, the spinal fusion bone graft substitute market is segregated into Demineralized Bone Matrix (DBM), bone morphogenetic proteins, synthetic bone graft extenders, stem cell therapy, and visco supplements. Demineralized Bone Matrix (DBM) market held the largest share in 2014 owing to high prices and osteoinductivity associated with it. Demineralized bone matrix, being the most popular in the US, has a great scope in the North American market over the other procedures. The stem cell therapy market is expected to show a significant growth rate over the forecast period owing to the advantages associated with it, such as the greatest regenerative potential for bone healing and the potency of stem cells to replace any tissue type without the need of a donor. On the basis of materials used, the market is segmented into natural materials, ceramics, composites, and polymers.
Geographically, the spinal fusion bone graft substitutes market is segmented into North America, Europe, Asia Pacific, Latin America, and MEA (Middle East and Africa). North America has the largest share in the market followed by Europe in 2014. Presence of favorable reimbursement facilities, stringent healthcare reforms, and developed healthcare infrastructure in the U.S. are the factors associated with its high market share. Asia Pacific is expected to a lucrative growth rate over the forecast period owing to the increasing disposable income, growing geriatric population, and improving healthcare infrastructure in the developing economies such as India and China. Increasing use of these substitutes in developing countries owing to the presence of various high unmet needs and increasing spending capacity of patients in these countries are expected to fuel the market growth.
Key market players include DePuy Synthes, Stryker, MTF, AlloSource, Baxter, Wright Medical, Integra LifeSciences, Bacterin International, LifeNet Health, RTI Surgical. Biocomposites, Alphatec Spine, Arthrex, Berkeley Advanced Biomaterials, Biomet, Osteogenics, and Etex Corporation. According to data published by the Drugwatch, in 2011, Medtronic was the market leader with 44% shares of spinal fusion bone graft substitutes market. Companies are adopting various business strategies such as new product launch, merger & acquisition, and joint ventures to maintain a strong position in the market. For instance, in 2011, Stryker successfully acquired the leading manufacturer of bone graft substitutes, Orthovita for around USD 318 million.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.
"The quality of research they have done for us has been excellent..."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.